" class="no-js "lang="en-US"> NRx Pharmaceuticals Appoints Carrie M. Carretta as Senior Vice President of Clinical Development and Medical Affairs - Medtech Alert
Friday, March 29, 2024

NRx Pharmaceuticals Appoints Carrie M. Carretta as Senior Vice President of Clinical Development and Medical Affairs

NRx Pharmaceuticals, a clinical-stage central nervous system (CNS) biopharmaceutical company, has announced the appointment of Carrie Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President (VP), Clinical Development and Medical Affairs.  She will lead the Company’s clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director.

“The NRx team is excited to have attracted a clinician with deep experience as an investigator. Dr. Carretta’s wealth of knowledge will help drive our mission to develop a first-in-class lifesaving drug for suicidal depression and PTSD. She has invaluable experience in both front-line care and corporate drug development that will benefit both patients and shareholders.”, said Stephen Willard, Chief Executive Officer, and Director, NRx Pharmaceuticals.

Dr. Carretta has extensive leadership experience in the pharmaceutical industry, developing and executing strategies in medical, clinical scientific and regulatory affairs as well as hiring, developing, and managing diverse medical science and clinical teams globally. She brings with her an extensive network of key opinion leaders, health care providers and researchers worldwide. Dr. Carretta is the co-founder and managing partner at C&G Holdings, LLC and most recently worked for Boehringer Ingelheim Pharmaceuticals as the Executive Director, Therapeutic Area Head for Clinical Development and Medical Affairs leading the CNS and Ophthalmology areas. Prior to this role, Dr. Carretta served as the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.

Prior leadership roles at Juul Labs included developing infrastructure and strategies which supported the company’s consumer device and her work for Novartis contributed to medical excellence for Cosentyx®, Ilaris®, Entresto® and Kisquali®, with Bayer Pharmaceuticals for The Betaconnect™ autoinjector used with Betaseron®, and with Teva Pharmaceuticals for Adasuve®. In addition to her experience in the pharmaceutical industry, Dr. Carretta has acted as an investigator for numerous clinical trials and has worked extensively in clinical practice both in general and forensic psychiatry, and in academia as a funded researcher.

Dr. Carretta holds a doctorate degree in Nursing from Vanderbilt University and both master’s and bachelor’s degrees in Nursing from Rutgers, The State University of New Jersey. She is nationally board-certified as an APN-BC, AHN-BC & PMHNP. Dr. Carretta is a current visiting scholar at Stanford University, Center for Precision Mental Health and Wellness.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more